Venetoclax

2:20
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
4:15
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
04:20
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
2:51
Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
3:31
CLL updates from ASH 2018: ibrutinib is the treatment of choice
John Gribben
1:39
Venetoclax monotherapy in MCL: longer-term results
Matthew Davids
4:31
Personalized AML therapy with John Byrd: the beat AML trial and more
John Byrd
1:48
A new era for elderly AML patients
Farhad Ravandi
2:25
Analyzing AML: novel therapies in review
Farhad Ravandi
1:48
Venetoclax for treating CLL outside the clinical trial setting
Lindsey Roeker
1:06
Current hurdles in the treatment of CLL
Lindsey Roeker
4:32
The current treatment landscape for CLL
John Gribben
2:11
AML highlights from ASH 2018
Guillermo Garcia-Manero
0:36
COSMOS: key updates for MOR208 plus venetoclax for R/R CLL
Jennifer Woyach
3:04
CLL news from ASH 2018: ibrutinib strikes again!
Stephan Stilgenbauer
5:26
Specific BCL2 mutation confers resistance to venetoclax in progressive CLL
Piers Blombery
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals